Novan presentation at the 23rd World Congress of Dermatology

Novan Therapeutics, a clinical-stage biotechnology company focused on advancing innovation in dermatology via nitric oxide therapies, today announced that following topical application of SB204 there was no measurable systemic exposure in patients with acne vulgaris. SB204 was generally well-tolerated and not associated with any significant safety issues under maximal use conditions in a Phase 1 clinical study in adults with moderate-to-severe acne. The results will be reported this afternoon in a featured poster presentation, titled “Pharmacokinetics of SB204 in Subjects with Acne Vulgaris,” at the 23rd World Congress of Dermatology (WCD), which is currently taking place in Vancouver, Canada.